LUND, SE / ACCESS Newswire / April 29, 2025 / BioInvent International (STO:BINV)
"The first quarter of 2025 was a highly productive period across clinical development, regulatory milestones, and strategic partnerships - positioning us for strong momentum through the remainder of the year."- Martin Welschof CEO of BioInvent.
EVENTS IN THE FIRST QUARTER
(R) Positive initial efficacy data from Phase 2a trial of triple combination of the company's lead anti-FcyRIIB antibody BI-1206, rituximab and Calquence ® for the treatment of non-Hodgkin's Lymphoma (NHL)
(R) Phase 1 data of the company's second anti-TNFR2 antibody BI-1910 as monotherapy for the treatment of solid tumors
BioInvent achieved ISO 26000 Verification, highlighting commitment to ESG and transparency
Composition of matter patent for the lead anti-TNFR2 antibody BI-1808 granted in Japan. It also covers the use of the antibody in the treatment of cancer
BI-1808 received Orphan Drug Designation from FDA for the treatment of T-cell lymphoma
BI-1808 showcased at the 16th Annual T-Cell Lymphoma Forum
EVENTS AFTER THE END OF THE PERIOD
BioInvent received milestone payment as Takeda moved mezagitamab into Phase 3
(R)= Regulatory event
FINANCIAL INFORMATION
First quarter 2025
Net sales SEK 22.1 (5.9) million.
Profit/loss after tax SEK -116.6 (-77.9) million.
Profit/loss after tax per share before and after dilution SEK -1.77 (1.18).
Cash flow from operating activities SEK -120.0 (-65.9) million.
Liquid funds, current and long-term investments at the end of the period SEK 742.2 (1,219.2) million.
The complete interim report is available for download below and on the company's website under Financial reports .
About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory drug candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com .
For further information, please contact:
Cecilia Hofvander, VP Investor Relations
Phone: +46 (0)46 286 85 50
Email: cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No.: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
Attachments
BioInvent Q1, 2025 EN
SOURCE: BioInvent International
View the original press release on ACCESS Newswire
